Post-progression outcomes following BCMA-directed CAR T-cell therapy in myeloma: impact of extramedullary and paramedullary disease

IntroductionBCMA-directed CAR T-cell therapies have improved outcomes in relapsed and refractory multiple myeloma (MM); however, the majority of patients relapse within 1 to 3 years following treatment. Managing disease progression after CAR T-cell therapy remains a major challenge, particularly in...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Ziad Abuhelwa, Fnu Amisha, Wenyi Fan, Gabriel De Avila, Doris K. Hansen, Ariel F. Grajales-Cruz, Brandon Blue, Omar Castaneda, Hien Liu, Ciara L. Freeman, Taiga Nishihori, Frederick L. Locke, Kenneth H. Shain, Rachid Baz, Melissa Alsina
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Frontiers Media S.A. 2025-10-01
Ráidu:	Frontiers in Oncology
Fáttát:	multiple myeloma CAR T-cell therapy progression extramedullary disease survival outcomes
Liŋkkat:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1663814/full
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!